Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.21 USD | +0.15% | -0.68% | -11.93% |
03/06 | UroGen Pharma Appoints David Lin as New Chief Commercial Officer | CI |
14/05 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.93% | 48Cr | |
+18.72% | 12TCr | |
+14.19% | 11TCr | |
-4.93% | 2.42TCr | |
+3.23% | 2.28TCr | |
-10.44% | 1.8TCr | |
-41.74% | 1.64TCr | |
-13.31% | 1.64TCr | |
+2.44% | 1.36TCr | |
+27.89% | 1.17TCr |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024